Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial-Reference-Cited by-同舟云学术

Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial

Published:2015-02 Issue:2 Volume:15 Page:161-171
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Zhong Nan Shan,Sun Tieying,Zhuo Chao,D'Souza George,Lee Sang Haak,Lan Nguyen Huu,Chiang Chi-Huei,Wilson David,Sun Fang,Iaconis Joseph,Melnick David

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference25 articles.

1. Community-acquired pneumonia;Wunderink;N Engl J Med,2014

2. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region;Song;Int J Antimicrob Agents,2011

3. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults;Mandell;Clin Infect Dis,2007

4. Guidelines for the management of adult lower respiratory tract infections—full version;Woodhead;Clin Microbiol Infect,2011

5. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations;Gupta;Lung India,2012

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Use and Treatment Outcomes of Ceftaroline Fosamil in Patients with Complicated Skin and Soft Tissue Infection: A Multinational Retrospective Study;Infection and Drug Resistance;2024-07

2. Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study;JAC-Antimicrobial Resistance;2024-05-06

3. Antibiotic Strategies for Severe Community-Acquired Pneumonia;Seminars in Respiratory and Critical Care Medicine;2024-02-01

4. Risk of Multidrug-Resistant Pathogens in Severe Community-Acquired Pneumonia;Seminars in Respiratory and Critical Care Medicine;2024-02-01

5. Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?;Pathogens;2024-01-19